ArticleInternational urology and nephrology2026

C-reactive protein at pembrolizumab initiation and its trajectory from first-line chemotherapy as prognostic markers in metastatic urothelial carcinoma (YUSHIMA study).

Shugo Yajima et al.PubMed ↗Publisher ↗

No numbers read from the abstract.